Last reviewed · How we verify
Clopidogrel, cilostazol
This combination of clopidogrel and cilostazol works by inhibiting platelet aggregation through different pathways to reduce thrombotic events.
This combination of clopidogrel and cilostazol works by inhibiting platelet aggregation through different pathways to reduce thrombotic events. Used for Secondary prevention of thrombotic events in patients with coronary artery disease or cerebrovascular disease, Peripheral arterial disease.
At a glance
| Generic name | Clopidogrel, cilostazol |
|---|---|
| Also known as | Plavix, pletaal |
| Sponsor | Kyunghee University Medical Center |
| Drug class | Antiplatelet agent combination |
| Target | P2Y12 receptor (clopidogrel); phosphodiesterase-3 (cilostazol) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clopidogrel is a P2Y12 receptor antagonist that irreversibly blocks ADP-induced platelet aggregation, while cilostazol is a phosphodiesterase-3 inhibitor that increases cAMP levels in platelets, promoting vasodilation and further inhibiting platelet aggregation. Together, they provide dual antiplatelet effects to prevent clot formation.
Approved indications
- Secondary prevention of thrombotic events in patients with coronary artery disease or cerebrovascular disease
- Peripheral arterial disease
Common side effects
- Bleeding
- Headache
- Diarrhea
- Palpitations
- Tachycardia
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol (PHASE4)
- Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA (PHASE3)
- Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA (PHASE3)
- Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study
- Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases
- Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral HaemorrhaGe (ASPIRING)-Pilot Phase (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clopidogrel, cilostazol CI brief — competitive landscape report
- Clopidogrel, cilostazol updates RSS · CI watch RSS
- Kyunghee University Medical Center portfolio CI